Trending Stock News

Morgan Stanley China A Share Fund, Inc. (CAF) Forms $26.81 Double Top; 3 Analysts Covering Pluristem Therapeutics Inc. (PSTI)

Pluristem Therapeutics Inc. (NASDAQ:PSTI) Logo

Among 3 analysts covering Pluristem Therapeutics (NASDAQ:PSTI), 3 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Pluristem Therapeutics had 13 analyst reports since August 14, 2015 according to SRatingsIntel. The firm has “Buy” rating by H.C. Wainwright given on Wednesday, September 6. H.C. Wainwright maintained it with “Buy” rating and $3.5 target in Tuesday, January 16 report. The firm has “Buy” rating given on Tuesday, July 19 by H.C. Wainwright. Maxim Group upgraded Pluristem Therapeutics Inc. (NASDAQ:PSTI) on Monday, June 19 to “Buy” rating. As per Tuesday, December 22, the company rating was maintained by Maxim Group. The firm earned “Buy” rating on Monday, July 10 by Maxim Group. Maxim Group downgraded the shares of PSTI in report on Monday, February 13 to “Hold” rating. The firm has “Buy” rating given on Friday, August 14 by MLV. On Thursday, August 17 the stock rating was maintained by H.C. Wainwright with “Buy”. On Tuesday, August 18 the stock rating was maintained by Maxim Group with “Buy”. See Pluristem Therapeutics Inc. (NASDAQ:PSTI) latest ratings:

11/05/2018 Broker: H.C. Wainwright Rating: Buy New Target: $3.5000 Maintain
16/01/2018 Broker: H.C. Wainwright Rating: Buy New Target: $3.5 Maintain

Morgan Stanley China A Share Fund, Inc. (CAF) formed double top with $29.22 target or 9.00% above today’s $26.81 share price. Morgan Stanley China A Share Fund, Inc. (CAF) has $ valuation. The stock decreased 0.07% or $0.02 during the last trading session, reaching $26.81. About 82,044 shares traded. Morgan Stanley China A Share Fund, Inc. (NYSE:CAF) has risen 36.72% since June 13, 2017 and is uptrending. It has outperformed by 24.15% the S&P500.

Investors sentiment decreased to 0.92 in Q1 2018. Its down 0.75, from 1.67 in 2017Q4. It fall, as 8 investors sold Pluristem Therapeutics Inc. shares while 5 reduced holdings. 7 funds opened positions while 5 raised stakes. 3.29 million shares or 11.82% less from 3.73 million shares in 2017Q4 were reported. Raymond James Associate has 108,793 shares for 0% of their portfolio. Art Advsrs Lc holds 19,322 shares. Pnc Fincl Ser Gru Incorporated stated it has 0% in Pluristem Therapeutics Inc. (NASDAQ:PSTI). Morgan Stanley accumulated 0% or 7,050 shares. Menora Mivtachim Limited holds 0.04% or 1.00 million shares in its portfolio. Fin Advisers Limited Liability Company has 0% invested in Pluristem Therapeutics Inc. (NASDAQ:PSTI) for 29,112 shares. Atwood & Palmer accumulated 0% or 33 shares. Millennium Mgmt Ltd Liability Co owns 60,654 shares or 0% of their US portfolio. State Street Corp holds 24,624 shares. Virtu Fincl Limited Company accumulated 0% or 16,070 shares. Sabby Management Ltd Co holds 0% or 27,640 shares in its portfolio. 78,200 are owned by Hightower Limited. 3,934 were reported by Tower Research Capital (Trc). Susquehanna International Gp Limited Liability Partnership has invested 0% of its portfolio in Pluristem Therapeutics Inc. (NASDAQ:PSTI). The New York-based Van Eck Assocs has invested 0% in Pluristem Therapeutics Inc. (NASDAQ:PSTI).

The stock decreased 6.43% or $0.09 during the last trading session, reaching $1.31. About 5.52 million shares traded or 912.90% up from the average. Pluristem Therapeutics Inc. (NASDAQ:PSTI) has declined 4.29% since June 13, 2017 and is downtrending. It has underperformed by 16.86% the S&P500. Some Historical PSTI News: ; 25/04/2018 – PLURISTEM THERAPEUTICS INC – EXPECTS TO BEGIN PATIENT ENROLLMENT IN BOTH EUROPE AND U.S. DURING 2018; 25/04/2018 – PLURISTEM IN TALKS WITH SEVERAL EU COUNTRIES TO APPROVE STUDY; 08/05/2018 – Pluristem Therapeutics at Non-Deal Roadshow Hosted By Seaport; 25/04/2018 – PLURISTEM THERAPEUTICS INC – IN DISCUSSIONS WITH SEVERAL EU COUNTRIES TO APPROVE STUDY IN EUROPE; 01/05/2018 – Pluristem Therapeutics Access Event Set By Seaport for May. 8; 25/04/2018 – U.S. FDA CLEARS PLURISTEM’S PHASE lll STUDY IN TREATMENT OF MUSCLE INJURY FOLLOWING HIP FRACTURE SURGERY; 25/04/2018 – PLURISTEM SAYS MUSCLE INJURY TREATMENT STUDY CLEARED BY FDA; 30/04/2018 – FDA Clears Pluristem’s Investigational New Drug Application for PLX-R18 to Treat Victims Exposed to Acute Radiation; 26/03/2018 – Roger Jeffs, Former Co-CEO of United Therapeutics, Joins Pluristem’s Strategic Advisory Bd; 30/04/2018 – U.S. FDA Clears Pluristem’s IND to Treat Victims Exposed to Acute Radiation

Pluristem Therapeutics Inc., together with its subsidiary, Pluristem Ltd., operates as a bio-therapeutics firm in Israel. The company has market cap of $145.24 million. It focuses on the research, development, clinical trial, and manufacture of cell therapeutic products and related technologies for the treatment of various ischemic, inflammatory, and hematologic conditions, as well as autoimmune disorders. It currently has negative earnings. The firm develops PLacental eXpanded cell therapy products, including PLX-PAD cells, which is Phase III clinical trial for the treatment of critical limb ischemia (CLI) in patients ineligible for revascularization, recovery after surgery for femoral neck fracture, and acute radiation syndrome (ARS), as well as peripheral and cardiovascular, and orthopedic diseases.

More important recent Pluristem Therapeutics Inc. (NASDAQ:PSTI) news were published by: which released: “Pluristem’s PLX-PAD cells successful in mid-stage IC study; shares ahead 14% premarket” on June 12, 2018, also published article titled: “Pluristem Reports Positive Top-Line Results from Its Multinational Phase II Intermittent Claudication Study”, published: “Benzinga Pro’s 5 Stocks To Watch Today” on June 12, 2018. More interesting news about Pluristem Therapeutics Inc. (NASDAQ:PSTI) was released by: and their article: “UPDATE: Pluristem Therapeutics (PSTI) Announces Positive Top-Line Results from Multinational Phase II Clinical …” with publication date: June 12, 2018.

Pluristem Therapeutics Inc. (NASDAQ:PSTI) Institutional Positions Chart

Leave a Reply

Your email address will not be published. Required fields are marked *